Featured News by Tag: Signatera
Featured News
February
1
2023
LifeLabs launches Signatera, offering Canadians an innovative and personalized approach to managing cancer
February 1, 2023. – Toronto, ON: LifeLabs is pleased to share the launch of SignateraTM, a highly sensitive, personalized molecular residual disease assay (MRD) test developed by Natera for treatmen...
December
15
2022
LifeLabs forms new collaboration with Natera to offer molecular residual disease (MRD) testing for cancer in Canada
LifeLabs is pleased to announce its new collaboration with Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, to offer* personalized testing for cancer in Canada through Natera’...